DoH Policies screened during the period: 1 October 2021 - 31 December 2021
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact
Documents
- NICE Technology Appraisal TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (review of TA579) (PDF 514KB)
- NICE Clinical Guideline NG193 - Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (PDF 559KB)
- NICE Technology Appraisal TA728 - Midostaurin for treating advanced systemic mastocytosis (PDF 511KB)
- NICE Technology Appraisal TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (PDF 514KB)
- NICE Clinical Guideline NG195 - Neonatal infection: antibiotics for prevention and treatment (updates and replaces CG149) (PDF 515KB)
- NICE Technology Appraisal TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people (PDF 512KB)
- NICE Clinical Guideline NG196 - Atrial fibrillation: diagnosis and management (updates and replaces CG180) (PDF 512KB)
- NICE Technology Appraisal TA735 - Tofacitinib for treating juvenile idiopathic arthritis (PDF 514KB)
- NICE Technology Appraisal TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (review of TA490) (PDF 513KB)
- NICE Technology Appraisal TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (PDF 624KB)
- NICE Clinical Guideline NG202 - Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (partially updates TA139) (PDF 514KB)
- NICE Technology Appraisal TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema (PDF 512KB)
- NICE Technology Appraisal TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (review of TA492) (PDF 624KB)
- NICE Technology Appraisal TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (PDF 622KB)
- NICE Technology Appraisal TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (PDF 513KB)
- NICE Technology Appraisal TA742 - Selpercatinib for treating advanced thyroid cancer with RET alterations (PDF 513KB)
- NICE Technology Appraisal TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease (PDF 513KB)
- NICE Technology Appraisal TA744 - Upadacitinib for treating moderate rheumatoid arthritis (PDF 513KB)
- NICE Technology Appraisal TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (PDF 623KB)
- NICE Technology Appraisal TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases (PDF 622KB)
- NICE Technology Appraisal TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (PDF 513KB)
- NICE Technology Appraisal TA751 - Dupilumab for treating severe asthma with type 2 inflammation (PDF 514KB)
- COVID-status Certification (PDF 1126KB)
- McCloud Remedy - The Health and Social Care Pension Schemes (Amendment) Regulations (Northern Ireland) 2022 (PDF 590KB)
- Member Contributions – The Health and Social Care Pension Scheme (Member Contributions) Regulations (Northern Ireland) 2022 (PDF 409KB)